Wellington Management Group LLP Sells 11,951 Shares of Harrow, Inc. (NASDAQ:HROW)

Wellington Management Group LLP decreased its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 91,228 shares of the company's stock after selling 11,951 shares during the quarter. Wellington Management Group LLP owned 0.26% of Harrow worth $3,061,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of HROW. GF Fund Management CO. LTD. purchased a new position in Harrow in the 4th quarter worth about $25,000. Tower Research Capital LLC TRC raised its position in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Harrow in the 4th quarter worth about $78,000. AlphaQuest LLC raised its position in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after buying an additional 2,889 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in Harrow in the 4th quarter worth about $214,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Stock Performance

Shares of NASDAQ:HROW traded down $0.79 during mid-day trading on Thursday, reaching $28.72. 469,481 shares of the company traded hands, compared to its average volume of 498,650. The company's 50 day moving average price is $25.36 and its 200-day moving average price is $30.16. The firm has a market cap of $1.05 billion, a PE ratio of -30.55 and a beta of 0.41. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 52 week low of $16.87 and a 52 week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, equities analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of recent analyst reports. B. Riley decreased their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. HC Wainwright boosted their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.